The Emerging Role of Radiation Therapy in Renal Cell Carcinoma

Michael Christensen, Raquibul Hannan

Research output: Contribution to journalReview articlepeer-review


Advancements in radiation delivery technology have made it feasible to treat tumors with ablative radiation doses via stereotactic ablative radiation therapy (SAbR) at locations that were previously not possible. Renal cell cancer (RCC) was initially thought to be radioresistant, even considered toxic, in the era of conventional protracted course radiation. However, SAbR has been demonstrated to be safe and effective in providing local control to both primary and metastatic RCC by using ablative radiation doses. SAbR can be integrated with other local and systemic therapies to provide optimal management of RCC patients. We will discuss the rationale and available evidence for the integration and sequencing of SAbR with local and systemic therapies for RCC.

Original languageEnglish (US)
Article number4693
Issue number19
StatePublished - Oct 2022


  • IVC tumor thrombus
  • oligometastasis
  • oligoprogression
  • radiation
  • SAbR
  • SBRT

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'The Emerging Role of Radiation Therapy in Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this